|
|
|
| home > news > detailed info |
|
|
 INDUSTRY NEWS AND PRESS RELEASES |
High performance range of insulated shipping systems |
 |
|
Laminar Medica’s Chilltherm® Global range of high performance insulated shipping systems, from 4 to 1130 litres product volume, are designed to offer optimal thermal protection for pharmaceutical products when exposed to extreme climates from -20°C to +40°C.
These shipping systems are pre-qualified to maintain payload integrity between +2°C and +8°C for transit durations of up to 120 hours. Real live data profiles have been used to give customers confidence that the quality and efficacy of their payloads will not be compromised during even the most demanding external temperatures. Cross hemisphere profile testing makes it ideal for clients making transcontinental shipments.
With only three sizes of cool packs used across the range and a common bill of materials for summer and winter pack outs the impact to warehousing and handling is minimised. |
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Novozymes VELTIS® half-life extension technology used by GlaxoSmithKline in type 2 diabetes drug approved in Europe
Copenhagen, Denmark – 31 March 2014 – Novozymes Biopharma DK A/S,
a subsidiary of Novozymes A/S, a world leader in bioinnovation, has
announced that its albumin-based VELTIS half-life extension technology
is being used by GlaxoSmithKline in the recently authorized Eperzan®
(albiglutide) for the treatment of type 2 diabetes in Europe.
More info >> |
|
 |
White Papers |
 |
|
Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections
IBT Bioservices
Introduction
Staphylococcus aureus (SA) is a ubiquitous, formidable
Gram-positive pathogen associated with skin and soft tissue, as well as
lifethreatening systemic infections. SA is a leading cause of hospital- and
community-associated infections worldwide, affecting humans and animals. The
wide range of pathologies reflects the diverse abilities of this microbe to
escape the innate and adaptive immune response using virulence factors. Since
its first emergence in the 1960s methicillin-resistant SA (MRSA) has become
endemic in hospitals and healthcare settings worldwide. In the 1990s, community
associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a
major global challenge.
More info >> |
|
 |
Industry Events |
 |
3rd Annual ClinTech EU
20-21 May 2014, Dublin, Ireland
ClinTech EU provides the
opportunity for clinical executives, business system owners and their teams to
come together to learn the latest applications of clinical technology to
facilitate the operational effectiveness of clinical trials.
More info >> |
|
|
